IQVIA Holdings In…
USUSDIQVIA Holdings Inc (US:IQV) — Biotechnology: Commercial Physical & Biological Resarch. Количество бирж, на которых торгуются акции компании: 2. На этой странице — цена и график, дивиденды, крупнейшие держатели и история количества акций.
О Компании
- Сайт
- iqvia.com
- Взаимодействие с Инвесторами
- ir.iqvia.com/
- Сектор
- Health Care · Biotechnology: Commercial Physical & Biological Resarch
- Штаб-Квартира
- Durham, United States
- Генеральный Директор
- Ari Bousbib
- Сотрудники
- 94 000
- Основана
- 2016
- Акций в Обращении
- 164.6 млн на 2026-07-21
- Свободное Обращение
- 156.25 млн
- Рыночная Капитализация
- 44.25 млрд USD
- Инсайдеры
- 1.09%
- Институциональные Инвесторы
- 103.42%
- Отрасль (SIC)
- Services-Commercial Physical & Biological Research
- ISIN
- US46266C1053
- LEI
- 549300W3R20NM4KQPH86
- P/E
- 32.8
- Коэффициент Выплат
- 41.0%
- FCF
- 2.12 млрд USD
- Выплаты / FCF
- 27%
- Долг
- 15.8 млрд USD6.6 г. FCF
- Стаж Дивидендов
- —
- Прибыль, FCF и выплаченные дивиденды — за 12 месяцев до 31.03.2026 (последний отчёт компании).
- NAV
Описание
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
Дивиденды
Выплаты дивидендов не обнаружены (проверено 16.10.2026). Компания, вероятно, не выплачивает дивиденды.
Новости Этой Недели
Пресс-релизы с сайта для инвесторов компании, обновляемые ежедневно. Ссылки ведут на сайт компании. Заголовки написаны на оригинальном языке, как и на сайте компании.
Крупнейшие Держатели
| Держатель | Доля | Акции | Дата Отчета |
|---|---|---|---|
| Blackrock Inc. | 8.84% | 14.55 млн | 2026-06-30 |
| Harris Associates L.P. | 7.4% | 12.18 млн | 2026-06-30 |
| Vanguard Capital Managem… | 6.63% | 10.91 млн | 2026-06-30 |
| State Street Corporation | 4.56% | 7.51 млн | 2026-06-30 |
| Vanguard Portfolio Manag… | 4.56% | 7.5 млн | 2026-06-30 |
| JPMORGAN CHASE & CO | 3.73% | 6.14 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.22% | 5.3 млн | 2026-06-30 |
| Artisan Partners Limited… | 2.88% | 4.74 млн | 2026-06-30 |
| Boston Partners | 2.71% | 4.47 млн | 2026-06-30 |
| Geode Capital Management… | 2.71% | 4.45 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.63% | 4.32 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.2% | 3.62 млн | 2026-06-30 |
| Invesco Ltd. | 1.99% | 3.28 млн | 2026-06-30 |
| HARRIS ASSOCIATES INVEST… | 1.58% | 2.61 млн | 2026-06-30 |
| HARRIS ASSOCIATES INVEST… | 1.56% | 2.57 млн | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 2.22 млн | 2026-08-31 |
| Fidelity Concord Street… | 1.31% | 2.16 млн | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.24% | 2.04 млн | 2026-08-31 |
| VANGUARD WINDSOR FUNDS-V… | 1.07% | 1.76 млн | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 0.96% | 1.59 млн | 2026-06-30 |
| BOUSBIB ARI B (Chief Exe… | ≈0.84% | 1.38 млн | 2026-07-29 |
| BRUEHLMAN RONALD E (Chie… | ≈0.03% | 55 996 | 2026-02-06 |
| HAAS BERND (Officer) | ≈0.01% | 24 414 | 2026-02-06 |
| GRENFELL ALISTAIR (Offic… | ≈0.01% | 24 124 | 2026-02-06 |
| SHERBET ERIC M (General… | ≈0.01% | 20 999 | 2026-07-29 |
| LEONARD JOHN M (Director… | ≈0.01% | 16 946 | 2026-04-23 |
| GOGGINS COLLEEN A (Direc… | ≈0.01% | 14 453 | 2026-04-23 |
| STAUB WALTER. RICHARD II… | ≈0.01% | 13 312 | 2026-08-03 |
| FEDOCK MICHAEL J. (Offic… | ≈0.01% | 9 595 | 2026-02-06 |
| DANHAKL JOHN G (Director… | — | — | 2026-04-23 |
